PET and SPECT Imaging of Tumor Biology: New Approaches Towards Oncology Drug Discovery and Development

Dort, Marcian E. Van; Rehemtulla, Alnawaz; Ross, Brian D.

doi:10.2174/157340908783769265

Cited by 41 publications

(22 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8͒. 101 Radiopharmaceuticals research has been the field of application of the first preclinical scanners. 102 However, the high spatial resolution and sensitivity that they offered opened new paths for preclinical SPECT and pushed molecular imaging to other exciting applications including neurodegenerative diseases, psychiatric disorders, inflammation, gene expression, and protein function.…”

Section: Micro-spectmentioning

confidence: 99%

In vivo small animal imaging: Current status and future prospects

et al. 2010

View full text Add to dashboard Cite

The use of small animal models in basic and preclinical sciences constitutes an integral part of testing new pharmaceutical agents prior to commercial translation to clinical practice. Whole-body small animal imaging is a particularly elegant and cost-effective experimental platform for the timely validation and commercialization of novel agents from the bench to the bedside. Biomedical imaging is now listed along with genomics, proteomics, and metabolomics as an integral part of biological and medical sciences. Miniaturized versions of clinical diagnostic modalities, including but not limited to microcomputed tomography, micromagnetic resonance tomography, microsinglephoton-emission tomography, micropositron-emission tomography, optical imaging, digital angiography, and ultrasound, have all greatly improved our investigative abilities to longitudinally study various experimental models of human disease in mice and rodents. After an exhaustive literature search, the authors present a concise and critical review of in vivo small animal imaging, focusing on currently available modalities as well as emerging imaging technologies on one side and molecularly targeted contrast agents on the other. Aforementioned scientific topics are analyzed in the context of cancer angiogenesis and innovative antiangiogenic strategies under-the-way to the clinic. Proposed hybrid approaches for diagnosis and targeted site-specific therapy are highlighted to offer an intriguing glimpse of the future.

show abstract

Section: Micro-spectmentioning

confidence: 99%

In vivo small animal imaging: Current status and future prospects

et al. 2010

View full text Add to dashboard Cite

show abstract

“…2 Indeed, molecular imaging studies using radiopharmaceuticals are oriented towards receptor-based studies, 3,4 because this approach is helpful in confirming the mechanism of action at the molecular level and in obtaining information such as receptor density and occupancy. 5,6 Promising anti-angiogenic treatments for cancer therapy have become well-established in recent years. Angiogenesis, consisting of the generation of new capillaries from existing blood vessels, is a common process associated to several pathological processes, including the growth of tumor tissues.…”

Section: Introductionmentioning

confidence: 99%

Radiosynthesis and micro-SPECT analysis of triazole-based RGD integrin ligands as non-peptide molecular imaging probes for angiogenesis

Bianchini

Fabbrizzi

Menchi

et al. 2015

Bioorganic & Medicinal Chemistry

View full text Add to dashboard Cite

“…Currently, various non-invasive imaging modalities such as computed X-ray tomography (CT), magnetic resonance imaging (MRI), ultrasound imaging (USI), positron emission tomography (PET) and single photon emission spectroscopy (SPECT) are used in the diagnosis of various diseases [1,2]. Each imaging modality has its own applications, merits and demerits.…”

Section: Introductionmentioning

confidence: 99%

Silver and Gadolinium Ions Co-substituted Hydroxyapatite Nanoparticles as Bimodal Contrast Agent for Medical Imaging

Madhumathi¹,

Ts²,

T³

et al. 2014

Bioceram Dev Appl

View full text Add to dashboard Cite

Developing multimodal contrast agents is an upcoming area and hydroxyapatite nanoparticles substituted with various elements like gadolinium, eurobium etc., seems to be a promising contrast agent, especially for multimodal imaging of bone-tissue interface. A bimodal contrast agent using silver (Ag + ) and gadolinium (Gd 3+ ) ions co-substituted hydroxyapatite nanoparticles has been developed for X-ray and magnetic resonance imaging. Ag + and Gd 3+ ions were co-substituted into hydroxyapatite at various atomic percentages (Ag:Gd=0.25:0.25, 0.25:0.5, 0.25:0.75) using microwave accelerated wet chemical synthesis. Pure as well as Ag + and Gd 3+ ions substituted hydroxyapatite samples were also synthesized for comparison. All samples were characterized by X-ray diffraction, Fourier transform infrared spectroscopy, transmission electron microscopy etc., and found to be monophasic, nanocrystalline with the substituted ions. These co-substituted hydroxyapatite samples were then tested in different diagnostic modalities such as X-ray, computed tomography imaging and magnetic resonance imaging. Appreciable variation in contrast was observed with different amount of substitutions. All the Ag + and Gd 3+ ions co-substituted hydroxyapatite nanoparticles showed higher contrast in all imaging modalities compared to those substituted with either Ag + or Gd 3+ ions only. Hydroxyapatite sample co-substituted with 0.25Ag and 0.75Gd at. % substitution showed the best bimodal CT-MRI contrast.

show abstract

PET and SPECT Imaging of Tumor Biology: New Approaches Towards Oncology Drug Discovery and Development

Cited by 41 publications

References 71 publications

In vivo small animal imaging: Current status and future prospects

In vivo small animal imaging: Current status and future prospects

Radiosynthesis and micro-SPECT analysis of triazole-based RGD integrin ligands as non-peptide molecular imaging probes for angiogenesis

Silver and Gadolinium Ions Co-substituted Hydroxyapatite Nanoparticles as Bimodal Contrast Agent for Medical Imaging

Contact Info

Product

Resources

About